Crinetics Pharmaceuticals, Inc. (DELISTED) (CRNX:DL)
84.95
0.00 (0.00%)
USD |
NASDAQ |
Sep 10, 16:00
Crinetics Pharmaceuticals Net Income (Quarterly) : -120.86M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -120.86M |
| March 31, 2026 | -127.84M |
| December 31, 2025 | -122.82M |
| September 30, 2025 | -130.09M |
| June 30, 2025 | -115.64M |
| March 31, 2025 | -96.77M |
| December 31, 2024 | -80.60M |
| September 30, 2024 | -76.83M |
| June 30, 2024 | -74.06M |
| March 31, 2024 | -66.93M |
| December 31, 2023 | -60.10M |
| September 30, 2023 | -57.46M |
| June 30, 2023 | -50.98M |
| March 31, 2023 | -46.00M |
| December 31, 2022 | -44.99M |
| September 30, 2022 | -41.92M |
| June 30, 2022 | -42.38M |
| March 31, 2022 | -34.63M |
| December 31, 2021 | -30.79M |
| Date | Value |
|---|---|
| September 30, 2021 | -27.85M |
| June 30, 2021 | -26.10M |
| March 31, 2021 | -22.90M |
| December 31, 2020 | -21.64M |
| September 30, 2020 | -18.32M |
| June 30, 2020 | -16.49M |
| March 31, 2020 | -17.36M |
| December 31, 2019 | -14.55M |
| September 30, 2019 | -14.43M |
| June 30, 2019 | -12.43M |
| March 31, 2019 | -9.016M |
| December 31, 2018 | -8.495M |
| September 30, 2018 | -7.588M |
| June 30, 2018 | -5.568M |
| March 31, 2018 | -5.464M |
| December 31, 2017 | -2.521M |
| September 30, 2017 | -2.382M |
| June 30, 2017 | -1.648M |
| March 31, 2017 | -2.606M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Vertex Pharmaceuticals, Inc. | 1.100B |
| Johnson & Johnson | 5.534B |
| Eli Lilly & Co. | 7.095B |
| Bristol Myers Squibb Co. | 3.316B |
| Corcept Therapeutics, Inc. | 42.14M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 25.12M |
| Total Expenses (Quarterly) | 145.97M |
| EPS Diluted (Quarterly) | -1.145 |
| Enterprise Value | 7.830B |
| Gross Profit Margin (Quarterly) | 95.12% |
| Profit Margin (Quarterly) | -481.1% |
| Earnings Yield | -5.94% |
| Normalized Earnings Yield | -5.939 |